Role of PLZF as a tumor suppressor in prostate cancer

Yang Jin; Hatice Zeynep Nenseth; Fahri Saatcioglu

doi:10.18632/oncotarget.19813

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Role of PLZF as a tumor suppressor in prostate cancer

Yang Jin _, Hatice Zeynep Nenseth and Fahri Saatcioglu

PDF | HTML | How to cite

Oncotarget. 2017; 8:71317-71324. https://doi.org/10.18632/oncotarget.19813

Metrics: PDF 1984 views | HTML 3487 views | ?

Abstract

Yang Jin1, Hatice Zeynep Nenseth2 and Fahri Saatcioglu1,2

1Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway

2Department of Biosciences, University of Oslo, Oslo, Norway

Correspondence to:

Yang Jin, email: [email protected]

Fahri Saatcioglu, email: [email protected]

Keywords: promyelocytic leukemia zinc finger, prostate cancer, tumor suppressor, androgens

Received: March 16, 2017 Accepted: July 12, 2017 Published: August 02, 2017

ABSTRACT

The promyelocytic leukemia zinc finger (PLZF), also known as ZBTB16 (Zinc Finger And BTB Domain Containing 16), is a transcription factor involved in the regulation of diverse biological processes, including cell proliferation, differentiation, organ development, stem cell maintenance and innate immune cell development. A number of recent studies have now implicated PLZF in cancer progression as a tumor suppressor. However, in certain cancer types, PLZF may function as an oncoprotein. Here, we summarize our current knowledge on the role of PLZF in various cancer types, in particular prostate cancer, including its deregulation, genomic alterations and potential functions in prostate cancer progression.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19813

Publication Alerts

Reviews:

Role of PLZF as a tumor suppressor in prostate cancer

Abstract